What does LIFESTREAM PHARMA do?

LIFESTREAM PHARMA is a wholesaler in Seneffe. Public Limited, started on 7 March 2000, 1 establishment.

What is the address of LIFESTREAM PHARMA?

The registered office of LIFESTREAM PHARMA is located at Rue Jules Bordet 69, 7180 Seneffe.

Is LIFESTREAM PHARMA still active?

Yes. According to the CBE (30 October 2026) LIFESTREAM PHARMA is active, legal situation “Normale toestand”, started on 7 March 2000.

Is LIFESTREAM PHARMA registered on Peppol?

Yes, LIFESTREAM PHARMA is registered on the Peppol network with ID 0208:0471383178.

What is the enterprise number of LIFESTREAM PHARMA?

The enterprise number of LIFESTREAM PHARMA is BE0471383178.

When was LIFESTREAM PHARMA founded?

LIFESTREAM PHARMA was founded on 7 March 2000.

Who are the directors of LIFESTREAM PHARMA?

According to the 2025 annual accounts, the directors of LIFESTREAM PHARMA are: Susan Fowler, John-fils Hathaway, John Hathaway, John Hauck, Michel Knops.

Is LIFESTREAM PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 March 2000; 5 annual accounts filed, latest fiscal year 2025; 5 directors known from the annual account.

How much profit did LIFESTREAM PHARMA make in 2025?

LIFESTREAM PHARMA recorded a loss after taxes of € 99,084 in financial year 2025.

What is the revenue of LIFESTREAM PHARMA?

As a small company, LIFESTREAM PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 166,688.

Does LIFESTREAM PHARMA have a website?

Yes, LIFESTREAM PHARMA has a website at telixpharma.com.

LIFESTREAM PHARMA (Public Limited) - Seneffe

Dossier LIFESTREAM PHARMA, printed on 30 October 2026 from databakkes.be/en/0471383178/lifestream-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

LIFESTREAM PHARMA from Seneffe, company number BE0471383178, closed financial year 2025 with a result of € -99,084 after tax. For that financial year LIFESTREAM PHARMA recorded a gross margin of € 166,688 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 34,333 to € -99,084. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.

What it is worth Healthy

€ 1.1 million

▼ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -99,084

▼ still € 34,333 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 581,918

▲ 66% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -757,166.

People and assets in 2025

Vehicles and equipment

€ 1,707

▼ 23% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 60,631

▼ 50% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 234,264

▲ 161% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 20,678 Gross margin 2022: € 20,678 First fiscal year in the series	€ 378,065 Gross margin 2023: € 378,065 ▲ € 357,387 vs 2022 (€ 20,678) Favourable step	€ 243,992 Gross margin 2024: € 243,992 ▼ 35% vs 2023 (€ 378,065) Unfavourable step	€ 166,688 Gross margin 2025: € 166,688 ▼ 32% vs 2024 (€ 243,992) Unfavourable step	▼ 32%
Profit after taxes	€ -118,659 Profit after taxes 2022: € -118,659 First fiscal year in the series	€ 190,996 Profit after taxes 2023: € 190,996 ▲ € 309,654 vs 2022 (€ -118,659) Favourable step	€ 34,333 Profit after taxes 2024: € 34,333 ▼ 82% vs 2023 (€ 190,996) Unfavourable step	€ -99,084 Profit after taxes 2025: € -99,084 ▼ € 133,417 vs 2024 (€ 34,333) Unfavourable step	▼ € 133,417
Equity	€ 1,267,584 Equity 2022: € 1,267,584 First fiscal year in the series	€ 1,258,580 Equity 2023: € 1,258,580 ▼ 1% vs 2022 (€ 1,267,584) Unfavourable step	€ 1,177,913 Equity 2024: € 1,177,913 ▼ 6% vs 2023 (€ 1,258,580) Unfavourable step	€ 1,078,829 Equity 2025: € 1,078,829 ▼ 8% vs 2024 (€ 1,177,913) Unfavourable step	▼ 8%
Total debts	€ 282,517 Total debts 2022: € 282,517 First fiscal year in the series	€ 484,477 Total debts 2023: € 484,477 ▲ 71% vs 2022 (€ 282,517) Unfavourable step	€ 210,050 Total debts 2024: € 210,050 ▼ 57% vs 2023 (€ 484,477) Favourable step	€ 297,784 Total debts 2025: € 297,784 ▲ 42% vs 2024 (€ 210,050) Unfavourable step	▲ 42%
Cash	€ 417,418 Cash 2022: € 417,418 First fiscal year in the series	€ 256,812 Cash 2023: € 256,812 ▼ 38% vs 2022 (€ 417,418) Unfavourable step	€ 351,309 Cash 2024: € 351,309 ▲ 37% vs 2023 (€ 256,812) Favourable step	€ 581,918 Cash 2025: € 581,918 ▲ 66% vs 2024 (€ 351,309) Favourable step	▲ 66%
Retained profit	€ -568,411 Retained profit 2022: € -568,411 First fiscal year in the series	€ -577,415 Retained profit 2023: € -577,415 ▼ € 9,004 vs 2022 (€ -568,411) Unfavourable step	€ -658,083 Retained profit 2024: € -658,083 ▼ € 80,667 vs 2023 (€ -577,415) Unfavourable step	€ -757,166 Retained profit 2025: € -757,166 ▼ € 99,084 vs 2024 (€ -658,083) Unfavourable step	▼ € 99,084
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 200,000 Dividend 2023: € 200,000 Unchanged (€ 0) Unchanged	€ 115,000 Dividend 2024: € 115,000 ▼ 42% vs 2023 (€ 200,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 115,000) Unchanged	▼ 100%
Bank debt	€ 240,713 Bank debt 2022: € 240,713 First fiscal year in the series	€ 466,689 Bank debt 2023: € 466,689 ▲ 94% vs 2022 (€ 240,713) Unfavourable step	€ 120,216 Bank debt 2024: € 120,216 ▼ 74% vs 2023 (€ 466,689) Favourable step	€ 60,631 Bank debt 2025: € 60,631 ▼ 50% vs 2024 (€ 120,216) Favourable step	▼ 50%
Balance sheet total	€ 1,550,101 Balance sheet total 2022: € 1,550,101 First fiscal year in the series	€ 1,743,057 Balance sheet total 2023: € 1,743,057 ▲ 12% vs 2022 (€ 1,550,101) Unchanged	€ 1,387,963 Balance sheet total 2024: € 1,387,963 ▼ 20% vs 2023 (€ 1,743,057) Unchanged	€ 1,376,613 Balance sheet total 2025: € 1,376,613 ▼ 1% vs 2024 (€ 1,387,963) Unchanged	▼ 1%

Key figures of LIFESTREAM PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to LIFESTREAM PHARMA?

What happened at LIFESTREAM PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 John-fils Hathaway stepped down as director. NBB
2031 John Hathaway stepped down as director. NBB
2031 John Hauck stepped down as director. NBB
Jun 22, 2026 New annual accounts for financial year 2025: loss of € 99,084 (▼ € 133,417 vs 2024). Source: NBB ↗
2025 Susan Fowler stepped down as director. NBB
2025 John-fils Hathaway became a director. NBB
2025 John Hathaway became a director. NBB
2025 John Hauck became a director. NBB

In short

From € 118,659 loss in 2022 to € 99,084 loss in 2025.

Best year ever: 2023, with € 190,996 profit.

Paid out € 315,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

LE CONDITIONNEMENT BELGE 100%

The stake of LE CONDITIONNEMENT BELGE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

LIFESTREAM PHARMA

The shares are held by LE CONDITIONNEMENT BELGE (100%).

Directors

According to the 2025 annual accounts

Susan Fowler

Director

since 2022 · until 2025

John-fils Hathaway

Director

since 2025 · until 2031

John Hathaway

Director

since 2025 · until 2031

John Hauck

Director

since 2025 · until 2031

Michel Knops

Director

Also active at: LE CONDITIONNEMENT BELGE, EUROPEAN HAIR CARE, IMMO-K

since 2022 · until 2025

Shareholders

LE CONDITIONNEMENT BELGE

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Jules Bordet 69

7180 Seneffe

2.093.783.897

Rue Jules Bordet z/n box Zone C

7180 Seneffe

Active since 14 April 2000

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.

All companies at this address →

LE CONDITIONNEMENT BELGE same network

€ 1.2 million gross margin · 2025

Facopar

€ 40,701 gross margin · 2025

EUROPEAN HAIR CARE same network

€ -4,852 gross margin · 2026

IMMO-K same network

€ 93,080 gross margin · 2025

CIFEL

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS telixpharma.com

About

Technologies

AWS S3ClarityCloudflare CDNContact Form 7Google AnalyticsMailchimpOneTrustPHPPWAPlausibleWordPressYoast SEOreCAPTCHA

Hosting & Email

Email provider

Mimecast

Hosting

CLOUDFLARENET - Cloudflare, Inc., US

Domain

telixpharma.com

Registered

2016-11-07

Registrar

Key-Systems GmbH

Expires

2026-11-07

Website info

HTTPS Ja

Languages EN

Features

Webshop Blog Jobs Newsletter Contact page

Security

✓ HTTPS

✗ SPF

✓ DMARC

Details

Company number: 0471.383.178
VAT number: BE 0471.383.178
Registered office: Rue Jules Bordet 69, 7180 Seneffe
Names & denominations: LIFESTREAM PHARMA
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 7 March 2000
Peppol: Active · Active since 19 Jan 2026
Contact: telixpharma.com
Activities · NACE: Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

LIFESTREAM PHARMA

Financials

What happened to LIFESTREAM PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Domain

Website info

Features

Security

Details

Frequently asked questions